The association effect of insulin and clonazepam on oxidative stress in liver of an experimental animal model of diabetes and depression.
BACKGROUND
It is known that oxidative stress occurs in peripheral blood in an experimental animal model of diabetes and depression, and acute treatment with insulin and clonazepam (CNZ) has a protective effect on oxidative stress in this model.


OBJECTIVE
This study evaluated the effect of insulin plus CNZ on oxidative stress parameters in the liver of diabetic male rats induced with streptozotocin (STZ) and subjected to forced swimming test (FST).


METHODS
Diabetes was induced by a single intraperitoneal (i.p.) dose of STZ 60 mg/kg in male Wistar rats. Insulin (4 IU/kg) plus CNZ acute i.p. treatment (0.25 mg/kg) was administered 24, 5 and 1 h before the FST. Nondiabetic control rats received i.p. injections of saline (1 mL/kg). Protein oxidative damage was evaluated by carbonyl formation and the antioxidant redox parameters were analyzed by the measurements of enzymatic activities of the superoxide dismutase (SOD), catalase and glyoxalase I (GLO). Glycemia levels also were determined.


RESULTS
Our present study has shown an increase in carbonyl content from diabetic rats subjected to FST (2.04 ± 0.55), while the activity of catalase (51.83 ± 19.02) and SOD (2.30 ± 1.23) were significantly decreased in liver from these animals, which were reverted by the treatment. Also, the activity of GLO (0.15 ± 0.02) in the liver of the animals was decreased.


CONCLUSIONS
Our findings showed that insulin plus CNZ acute treatment ameliorate the antioxidant redox parameters and protect against protein oxidative damage in the liver of diabetic rats subjected to FST.
Programa de Pós-Graduação em Ciências Farmacêuticas , Porto Alegre, RS , Brasil.
Carlos Alberto Yasin
CA
Wayhs
Caroline
C
Tortato
Caroline Paula
CP
Mescka
Matheus Augusto
MA
Pasquali
Carlos Eduardo
CE
Schnorr
Maurício Schüler
MS
Nin
Helena Maria Tannhauser
HM
Barros
José Claudio Fonseca
JC
Moreira
Carmen Regla
CR
Vargas
D000818:Animals; D002374:Catalase / Q000378:metabolism; D002998:Clonazepam / Q000008:administration & dosage / Q000494:pharmacology*; D003863:Depression / Q000188:drug therapy* / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D007791:Lactoylglutathione Lyase / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D050050:Protein Carbonylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D013482:Superoxide Dismutase / Q000378:metabolism; D013997:Time Factors
D007328:Insulin; D002998:Clonazepam; D013311:Streptozocin; D002374:Catalase; D013482:Superoxide Dismutase; D007791:Lactoylglutathione Lyase